Understanding Wound Care Risk-Share Models: What They Are and Why They Matter

You are tired of vendors promising savings but demanding fee-for-service contracts that reward volume.

We understand.

That is why at Old Mission Wound Care, we put our fees at risk. We set a baseline for your chronic wound population, we intervene with treatment, and if we don't reduce your total cost of care, you don't get paid — or we give money back.

Here is how the mechanics actually work.

What a Wound Care Risk-Share Model Actually Is

A risk-share model is a financial arrangement where we stop billing you per visit or per procedure and instead take responsibility for a defined clinical risk and its downstream cost.

If outcomes improve and total cost goes down, we share in the savings.

If outcomes miss, we give money back or lose margin.

Concretely, in wound care, that means:

• We agree on a baseline total cost of care for a defined wound population
• We take ownership of the clinical volatility—visits, supplies, grafts, complications, and care coordination
• If amputations, infections, ED visits, or readmissions drop below baseline, you keep most of the savings and we earn upside
• If they do not, our fees are at risk

In some models, we cap downside so you get cost certainty and we absorb the operational pain.

This is not a new payment wrapper around old behavior. This is outcome accountability.

Why Traditional Fee-For-Service Models Fail for Chronic Wounds

Fee-for-service wound care monetizes the wrong part of the cost curve.

Vendors get paid for visits, procedures, and supplies. But the real financial risk lives in hospitalizations, complications, and escalation events. Those costs sit on your balance sheet, not theirs.

Here is what the typical chronic wound cost curve looks like:

Months 0 to 2: Deceptively cheap

Early costs run $1,000 to $3,000 total. Office visits, basic supplies, occasional debridement. The wound feels manageable, almost ignorable.

This is why wounds are underestimated. Leadership assumes linear spend.

Months 3 to 6: Acceleration phase

The wound stalls or enlarges. Infection risk increases. The first ED visit or urgent admission happens.

One inpatient admission costs $12,000 to $25,000. Cumulative spend reaches $15,000 to $35,000.

The wound is no longer a nuisance. It is now a utilization driver.

Months 6 to 12: Catastrophic tail risk

Recurrent infections. Osteomyelitis. Multiple readmissions. Surgical escalation, sometimes amputation.

Total 12-month spend ranges from $40,000 to $60,000 on the conservative end. Common cases run $75,000 to $100,000 or more.

Research confirms this pattern. Average costs for diabetic foot ulcers show primary healed ulcers at $4,830, but major amputations reach $73,813 per episode.

The cost distribution looks like this:

• 15-20% of total cost occurs in the first 2 to 3 months
• 60-70% of total cost occurs after month 4
• A single event—one admission or surgery—often represents more cost than everything that came before it combined

That is what we mean by back-loaded spend.

Most of this cost lands late, after leadership has already lost the chance to intervene cheaply.

How We Establish the Baseline: No Marketing Math

When we talk about a baseline total cost of care, we are not guessing, benchmarking off national averages, or using marketing math.

We anchor to your own historical claims and utilization, then normalize for risk.

What data we look at:

We start with retrospective data, ideally 12 to 24 months if available. Minimum viable is 6 months, but longer is better.

Core claims and utilization:

• Wound-related inpatient admissions
• ED visits tied to wound complications
• Readmissions within 30 and 90 days
• Surgical events, debridements, amputations
• SNF stays triggered by wound deterioration
• Total wound-related professional and facility spend

Patient-level clinical signals:

• Wound type: DFU, VLU, pressure injury
• Severity markers: depth, infection, ischemia
• Comorbid burden: diabetes, CHF, CKD, PAD
• Recurrence rates, new ulcer formation within 6 to 12 months

Timing matters.

We look at when cost occurs, not just how much. Most wound spend is back-loaded—hospitalizations, complications, escalation. That is the risk we are isolating.

This is why we position ourselves as Old Mission Wound Care rather than a vendor. Vendors only see visits. We see downstream claims.

What the Risk Corridor Actually Means

A risk corridor is the set of financial guardrails that define how much volatility each side is willing to absorb.

It answers three questions a CFO will always ask, even if they don't say it out loud:

1. How much upside can you actually earn?
2. How much downside can you actually lose?
3. What happens if reality blows past expectations?

A risk corridor sets:

• A baseline total cost of care
• A neutral zone where neither side wins nor loses
• An upside band where savings are shared
• A downside band where fees are at risk or clawed back

The corridor exists to remove randomness and protect both parties from statistical noise, one bad outlier, or a freak year.

This structure is standard in value-based care. Risk corridors allow parties to share in cost or savings beyond certain thresholds—for example, if claim costs exceed 105% of a target amount, or fall below 95%.

Minimum population size matters.

Our minimum for a pilot is approximately 3,000 lives or 40 wound patients. Below 30 wound patients, the operational lift doesn't justify the contract size.

For context, most lives under care will have a 2.5% to 5% wound population. Break even for us is 3%. CKD-focused populations run 15% to 20% wound prevalence. Broad MA plans have around 2% to 2.5%.

Who This Wound Care Risk-Share Model Does Not Work For

Risk-share models are not appropriate for every organization.

You are not a good fit if…

1. You are not willing to share data

We need access to your claims and utilization data. If you cannot or will not provide it, we cannot establish a legitimate baseline.

2. Wound care is structurally fragmented

If wound care is distributed across multiple departments with no single owner, accountability becomes impossible. You need to be comfortable with one owner.

3. Leadership expects linear improvement

If you expect month-over-month cost reduction or immediate savings in the first 30 to 60 days, your expectations are unrealistic. Outcomes take time to materialize.

4. The organization cannot move upstream

If your system only engages once a patient is already hospitalized or septic, the math is upside down. We need to intervene early.

Our ideal entry point is within 7 to 14 days of wound identification.

At this point, the wound is still biologically recoverable. Infection is often local, not systemic. Vascular compromise can be identified before tissue loss. Total downstream cost is still optional, not inevitable.

From an economics standpoint, this is where we flatten the curve instead of chasing it.

30 to 45 days is acceptable but the window narrows. The wound may already be stalled. Early infections may have occurred. The first ED visit might already be on the books. Savings are still possible, but the risk corridor tightens. One bad event can wipe out upside.

Why Healthcare Organizations Are Exploring This Now

Healthcare organizations are considering risk-share now because the old buffers that absorbed inefficiency are gone, while downside exposure has become very real and very personal to finance and clinical leadership.

The momentum is measurable. Between 2012 and 2017, fewer than 10% of ACOs assumed downside risk. As of 2020, that number jumped to 37%.

In 2022, the Medicare Shared Savings Program saved Medicare $1.8 billion, with 63% of ACOs earning shared savings payments.

The industry is moving toward outcome accountability whether individual organizations are ready or not.

What Separates Legitimate Risk-Share Models from Marketing Language

You have heard this pitch before from other vendors.

Here is the difference between ownership and coordination.

A legitimate risk-share partner:

• Owns the wound patients from start to finish
• Controls clinical protocols
• Owns escalation pathways
• Has authority to intervene early without waiting for approvals

If a CFO is talking with a vendor and they say "not much" when asked what happens to them if outcomes don't improve, that is a red flag.

Here is what ownership looks like operationally:

A patient's wound isn't responding to initial treatment at day 21. In our model:

• Automatic stall trigger—not a suggestion. Our clinical team initiates without needing permission.
• Root-cause reclassification within 72 hours—is it a blood flow problem? Infection? Mechanical failure?
• Escalation execution—if vascular compromise is suspected, we direct referral to vascular. If infection risk is rising, we implement an antibiotic plan.
• Financial accountability is already live—our fees are at risk based on the outcome.

A mobile vendor would simply chart it. Identify it as "slow progress" and then either continue with visits or stop, collect their reimbursement, and anything that happens afterwards isn't their problem.

That is the structural difference.

What to Do in the Next 30 Days Before Talking to Any Vendor

If you are considering a risk-share model, do this homework first.

1. Pull a brutally simple wound cost snapshot (7 to 10 days)

You are not building a model. You are testing whether there is even something to manage.

Ask your team for one table covering the last 12 months:

• Total inpatient admissions with a chronic wound diagnosis present
• 30- and 90-day readmissions where a wound was a contributing factor
• ED visits tied to wound complications
• SNF days following wound-related admissions
• Total allowed cost for those encounters

If your team cannot produce this without heroic effort, that alone tells you something about readiness.

What you are looking for:

• Concentration of cost, not averages
• Late-stage spend, not clinic visits
• A small number of patients driving a disproportionate share of utilization

If the total number is immaterial, risk-share is unnecessary. If it is material and poorly understood, risk-share is worth exploring.

2. Identify where you first touch the patient (10 to 14 days)

This is the most important operational test.

Answer this question honestly: "Where do we usually encounter wound patients for the first time?"

Common answers:

• At hospital admission
• In the ED
• After multiple failed outpatient attempts
• After a prior hospitalization

If that is true, you are downstream.

Now ask:

• Who sees these patients before they escalate?
• How fast can they refer?
• Who owns early intervention authority?

If no one owns that upstream moment, no risk-share model will work, no matter how good the vendor is.

You don't need to fix it yet. You just need to know whether it exists.

3. Pressure-test your own appetite for accountability (30 days)

This is the quiet internal conversation most organizations skip.

Ask three direct questions in leadership:

1. Are we willing to agree on a baseline and let performance be measured against it?
2. Are we willing to let an external partner change care paths without committee delay?
3. Are we willing to accept uneven results early in exchange for reduced tail risk later?

If any of those answers are "no," stop.

Risk-share is not a procurement decision. It is a governance decision.

If leadership wants optional accountability, fee-for-service is safer and more honest.

If Wounds Drive Your Risk Curve, This Is The Moment to Take Control

If you don't understand your wound-related risk, can't engage early, or aren't ready to let outcomes drive economics, risk-share isn't premature—it is inappropriate.

When CFOs do this homework first, conversations with groups like Old Mission Wound Care become short, serious, and productive, not exploratory theater.

We are not interested in being another vendor on your approved list. We are interested in taking responsibility for a defined clinical risk and its downstream cost.

If that aligns with where your organization is heading, let's talk.